• 1
    Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 4654.
  • 2
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 3
    Schiller JT, Lowy DR. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 2001; 1: 57181.
  • 4
    Lowy DR, Frazer IH. Chapter 16: prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003; 31: 1116.
  • 5
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 164551.
  • 6
    Stanley MA. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines 2003; 2: 3819.
  • 7
    Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 3437.
  • 8
    Hegde RS. The papillomavirus E2 proteins: structure, function and biology. Annu Rev Biophys Biomol Struct 2002; 31: 34360.
  • 9
    Stevenson M, Hudson LC, Burns JE, Stewart RL, Wells M, Maitland NJ. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 2000; 81: 182532.
  • 10
    Selvakumar R, Ahmed R, Wettstein FO. Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus. Virology 1995; 208: 298302.
  • 11
    Rosales C, Graham VV, Rosas GA, Merchant H, Rosales R. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 2000; 49: 34760.
  • 12
    Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 2003; 16: 11121.
  • 13
    Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154: 593443.
  • 14
    Fernando GJ, Murray B, Zhou J, Frazer IH. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 1999; 115: 397403.
  • 15
    Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, Elmishad AG, Kast WM, Smith LR. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001; 61: 78617.
  • 16
    Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 1999; 73: 787781.
  • 17
    Moniz M, Ling M, Hung CF, Wu TC. HPV DNA vaccines. Front Biosci 2003; 8: d5568.
  • 18
    de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 4729.
  • 19
    Davidson EJ, Sehr P, Faulkner RL, Parish JL, Gaston K, Moore RA, Pawlita M, Kitchener HC, Stern PL. Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. J Gen Virol 2003; 84: 208997.
  • 20
    Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 18005.
  • 21
    Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001; 279: 3619.
  • 22
    Frazer I. Vaccines for papillomavirus infection. Virus Res 2002; 89: 2714.
  • 23
    Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999; 81: 8818.
  • 24
    Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class 1 α2 and α3 domains in the recognition of self and nonself MHC molecules. J Immunol 1996; 156: 247380.
  • 25
    Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. Embo J 1990; 9: 15360.
  • 26
    Prakash SS, Grossman SR, Pepinsky RB, Laimins LA, Androphy EJ. Amino acids necessary for DNA contact and dimerization imply novel motifs in the papillomavirus E2 trans-activator. Genes Dev 1992; 6: 10516.
  • 27
    Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78: 7517.
  • 28
    Harro et al., 2001 ???
  • 29
    Konya J, Eklund C, af Geijersstam V, Yuan F, Stuber G, Dillner J. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 1997; 78: 261520.
  • 30
    Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 2001; 13: 63341.
  • 31
    Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, Leggatt GR, Frazer IH. IL-10 mediates suppression of the CD8 T cell IFN-γ response to a novel viral epitope in a primed host. J Immunol 2003; 171: 476572.
  • 32
    Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 1998; 161: 456371.
  • 33
    Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 1997; 94: 1085661.
  • 34
    Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 2001; 13: 897908.
  • 35
    Moore RA, Walcott S, White KL, Anderson DM, Jain S, Lloyd A, Topley P, Thomsen L, Gough GW, Stanley MA. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology 2003; 314: 6305.
  • 36
    Han R, Cladel NM, Reed CA, Peng X, Budgeon LR, Pickel M, Christensen ND. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 2000; 74: 97126.
  • 37
    Han R, Reed CA, Cladel NM, Christensen ND. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 2000; 18: 293744.
  • 38
    Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003; 21: 321927.
  • 39
    Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003; 106: 2317.
  • 40
    Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001; 166: 534655.
  • 41
    Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, Dittrich C. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. Br J Cancer 2005; 92: 101925.
  • 42
    Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T, Plow EF. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 2005; 23: 826.
  • 43
    Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR. CD40 activation as potential tool in malignant neoplasms. Tumori 2002; 88: 3616.
  • 44
    Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999; 190: 12533.
  • 45
    Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 2002; 99: 130205.
  • 46
    Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, Kundig TM, Ruedl C, Bachmann MF. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002; 168: 28806.
  • 47
    Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJ. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 3508.
  • 48
    Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. Embo J 1997; 16: 50414.
  • 49
    Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002; 62: 57929.